disclosed a modified and detoxified anticholinergic neurotoxic peptide that can suppress and prevent the onset of a t - cell mediated autoimmune reaction . the invention has application to the treatment of certain human autoimmune diseases , including especially multiple sclerosis , myasthenia gravis , and rheumatoid arthritis . more specifically , the method of treatment of autoimmune disorders is to administer a disease mitigating amount of a detoxified and neurotropically active modified alpha - neurotoxin composition .